Volume 9, Issue 4 (4-2020)                   Clin Exc 2020, 9(4): 11-22 | Back to browse issues page

XML Persian Abstract Print


Associate Professor, Nutrition Society, Faculty of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract:   (4390 Views)
Non-Alcoholic Fatty Liver (NAFLD) is produced by liver pathological accumulation of fat and the prevalence of this disorder in the world is 35-36%. Evidence has shown that auxiliary treatments, including the use of antioxidant compounds, can be effective in improving non-alcoholic fatty liver. Resveratrol is a polyphenolic compound that has antioxidant properties. Other mechanisms of resveratrol have been shown to improve fatty liver.
Study Type: A systematic Review on Randomized Clinical Trials.
This study aimed to investigate the results of research on the relationship between supplementation of resveratrol and non-alcoholic fatty liver. Randomized Clinical Trials on the effect of supplementation of resveratrol on NAFLD from PubMed, Scopus, ISI and Google Scholar databases between 2000 and 2018 with the keywords: Resveratrol, Fatty Liver, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD Reviewed. 
Between most clinical trials have shown positive effects of resveratrol supplementation on the improvement of non-alcoholic fatty liver symptoms, including oxidative stress, inflammation, liver enzymes, and insulin resistance. There was also a decrease in fat content in the subjects. However, some studies have different results and do not show a significant effect on resveratrol supplementation.
In most studies, the positive effects of resveratrol supplementation on non-alcoholic fatty liver have been proven, but more studies are needed because of the controversy of the study.
Full-Text [PDF 408 kb]   (1867 Downloads)    
Type of Study: Review | Subject: تغذيه
Received: 2019/12/12 | Accepted: 2020/03/29 | Published: 2020/03/29

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.